Dr. Beaupre on Ibrutinib in Diffuse Large B-Cell Lymphoma

Darrin M. Beaupre, MD
Published: Thursday, Mar 30, 2017



Darrin M. Beaupre, MD, head of Early Development and Immunotherapy at Pharmacyclics, discusses a trial of ibrutinib (Imbruvica) in diffuse large B-cell lymphoma (DLBCL).

In a phase Ib/II trial combination of ibrutinib with lenalidomide (Revlimid) and rituximab (Rituxan) was tested in patients with the ABC subtype of DLBCL. Safety was determined first, and then in the phase II portion, the combination was tested at the maximum-tolerated dose. Ibrutinib with lenalidomide and rituximab was well tolerated up to a 25 mg dose of lenalidomide.

In the non-GCB subtype, there was a high overall response rate, and several patients did not have disease progression until after 1 year, says Beaupre.
 


Darrin M. Beaupre, MD, head of Early Development and Immunotherapy at Pharmacyclics, discusses a trial of ibrutinib (Imbruvica) in diffuse large B-cell lymphoma (DLBCL).

In a phase Ib/II trial combination of ibrutinib with lenalidomide (Revlimid) and rituximab (Rituxan) was tested in patients with the ABC subtype of DLBCL. Safety was determined first, and then in the phase II portion, the combination was tested at the maximum-tolerated dose. Ibrutinib with lenalidomide and rituximab was well tolerated up to a 25 mg dose of lenalidomide.

In the non-GCB subtype, there was a high overall response rate, and several patients did not have disease progression until after 1 year, says Beaupre.
 

View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Community Practice Connections™: Oncology Best Practice™ Decision Points in Advanced NSCLC: Assessing Treatment Options Beyond Disease ProgressionNov 30, 20181.0
Community Practice Connections™: Precision Medicine for Community Oncologists: Assessing the Role of Tumor-Testing Technologies in Cancer CareNov 30, 20181.0
Publication Bottom Border
Border Publication
x